Protagonist TherapeuticsPTGX
PTGX
About: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Employees: 130
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
54% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 76
24% more capital invested
Capital invested by funds: $3.15B [Q1] → $3.92B (+$768M) [Q2]
7.89% more ownership
Funds ownership: 106.38% [Q1] → 114.28% (+7.89%) [Q2]
2% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 49
0% more funds holding in top 10
Funds holding in top 10: 14 [Q1] → 14 (+0) [Q2]
2% less funds holding
Funds holding: 273 [Q1] → 268 (-5) [Q2]
27% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $15.9M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$69
21%
upside
Avg. target
$74
30%
upside
High target
$80
41%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jonathan Wolleben | 21%upside $69 | Market Outperform Maintained | 7 Aug 2025 |
Citigroup Geoff Meacham | 27%upside $72 | Buy Initiated | 17 Jun 2025 |
HC Wainwright & Co. Douglas Tsao | 41%upside $80 | Buy Reiterated | 3 Jun 2025 |
Financial journalist opinion
Based on 3 articles about PTGX published over the past 30 days
Neutral
The Motley Fool
2 weeks ago
Protagonist (PTGX) Q2 Revenue Falls 26%
Protagonist (PTGX) Q2 Revenue Falls 26%
Negative
Zacks Investment Research
2 weeks ago
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
Neutral
Accesswire
2 weeks ago
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th Phase 3 VERIFY trial data set of rusfertide in polycythemia vera (PV) presented during plenary session at ASCO; U.S. NDA filing on track for Q4 Cash, cash equivalents and marketable securities of $673.0 million as of June 30, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / August 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. "Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist, as we saw rusfertide the topic of the prestigious ASCO Plenary Session in May, the announcement of an oral and injectable triple agonist anti-obesity peptide development candidate in June, and most recently the first ever NDA filing of icotrokinra for psoriasis last month," said Dinesh V.
Neutral
Investors Business Daily
1 month ago
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.
Neutral
Accesswire
2 months ago
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13754335 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86 A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
Positive
Seeking Alpha
2 months ago
Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & Johnson and Takeda provide significant milestone payments, royalties, and potential for $500M–$1B annual revenue by 2030, I'd speculate. A robust cash position and a promising preclinical obesity program enhance Protagonist's strategic value and acquisition appeal.
Neutral
Business Wire
2 months ago
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeti.
Neutral
Accesswire
3 months ago
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Negative
Zacks Investment Research
3 months ago
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to earnings of $3.26 per share a year ago.
Neutral
Accesswire
3 months ago
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025 Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CALIFORNIA / ACCESS Newswire / May 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "Protagonist is off to a very strong 2025 with multiple transformational events in the first quarter for our two late-stage partnered assets, rusfertide and icotrokinra which are progressing to NDA filings by year end," said Dinesh V.
Charts implemented using Lightweight Charts™